Prescription drug freight fraud, April 2026

Over the last six months, freight fraud involving GLP-1 drugs was persistent and adaptive. Semaglutide and tirzepatide shippers evolved tactics to obscure origins, contents, and manufacturing sources. We observed familiar risks, unregistered facilities, residential “manufacturers,” and expanding code fraud.

Read the report and learn more about pharmaceutical border security.

What we found

Product-code mismatches in the antibiotics category were a consistent issue, with 19% of the 1,416 shipments declared as one thing but described in ITACS as another.

Shippers continued to obscure their packages’ true origins or list online pharmacies or residential addresses as manufacturers. Examples included:

Sites listed as manufacturers in FDA imports data. Used in the April 2026 freight fraud report. Images from Google maps.

A package from this pharmacy was refused entry. (Photo: Google maps)

This Marriott hotel was listed as a tirzepatide manufacturer. (Photo: Google maps)